Correlation of catecholamine content and clinical influencing factors in depression among psoriasis patients: a case-control study

Long, Si‐Qi; Fang, Jing; Shu, Hui-Ling; Xia, Dengmei; Wang, Zhengqun; Mi, Wen-Yao; Zhang, Xueli; Li, Chang-Qiang

doi:10.1186/s13030-022-00245-2

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding and monitoring such comorbidities, which is also known as the comorbidome, has become of paramount importance in order to choose the ideal biological therapy and customize follow-ups. Indeed, both epidemiological studies and murine models indicate that comorbidities may influence PsO progression and vice versa [ 6 , 7 ]. Multidisciplinary styles and interdisciplinary teamwork are thus essential when treating people with multiple comorbidities, in order to properly manage their illnesses [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis

Buja,

Miatton,

Cozzolino

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. Methods In a matched case–control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented. Results In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2–4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients’ specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88–7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96–4.77)], inflammatory bowel diseases [i.e., Crohn’s disease (OR 2.99 95% CI 2.20–4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61–2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36–3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30–2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57–1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41–1.53)]. Conclusion The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey.

show abstract

Section: Introductionmentioning

confidence: 99%